Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 2/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 16/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085584 | 0.82 | HSD17B10 (0.53) | PARGTP53KMT2A | |
| SCHEMBL10084699 | 0.77 | RORA (0.52) | PARGTP53KMT2A | |
| SCHEMBL10084678 | 0.75 | TP53 (0.53) | PARGTP53 | |
| SCHEMBL17824838 | 0.75 | PARG (1.00) | PARG | |
| SCHEMBL10085092 | 0.74 | POLB (0.43) | PARGKMT2A | |
| SCHEMBL5987056 | 0.73 | PIK3CG (0.58) | PARGTP53KMT2A | |
| SCHEMBL10084721 | 0.73 | TP53 (0.63) | PARGTP53KMT2A | |
| SCHEMBL10084493 | 0.72 | RORA (0.47) | PARGTP53KMT2A | |
| SCHEMBL10084710 | 0.72 | MEN1 (0.52) | PARGTP53KMT2A | |
| SCHEMBL17434218 | 0.72 | KDM4E (0.52) | PARGGRIN1GRIN2BTP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590975-B1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-8859544-B2 | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8859544-B2 | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| WO-2012004731-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, INMT, IDO1 | PARG 1457/4885GRIN1 1081/4885GRIN2B 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.